Insider Selling: Travere Therapeutics (NASDAQ:TVTX) CEO Sells 64,000 Shares of Stock

Key Points

• CEO Eric Dube sold 64,000 shares on April 15 at an average price of $41.09 for proceeds of $2.63M under a pre-arranged Rule 10b5-1 plan, reducing his stake by 12.88% to 432,886 shares (valued ≈ $17.79M).
• TVTX traded down about 2.8% to $40.95 on heavy volume (4.52M vs. average 2.20M), with a market capitalization of ~$3.78B and a 52-week range of $13.88–$43.31.
• FDA full approval for Filspari in FSGS sparked an ≈37% rally, prompted several analyst price-target upgrades, and left the stock with a consensus "Moderate Buy" and a $42.50 target.

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) CEO Eric Dube sold 64,000 shares of Travere Therapeutics stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $41.09, for a total transaction of $2,629,760.00. Following the completion of the sale, the chief executive officer owned 432,886 shares in the company, valued at $17,787,285.74. The trade was a 12.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Down 2.8%

TVTX stock traded down $1.18 during mid-day trading on Wednesday, reaching $40.95. The company had a trading volume of 4,521,912 shares, compared to its average volume of 2,203,580. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of -136.50 and a beta of 0.86. Travere Therapeutics, Inc. has a 52 week low of $13.88 and a 52 week high of $43.31. The stock has a 50 day simple moving average of $29.57 and a two-hundred day simple moving average of $31.37. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.74 and a quick ratio of 2.70.

Institutional Trading of Travere Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Emerald Advisers LLC boosted its holdings in Travere Therapeutics by 2.6% in the third quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company's stock worth $51,308,000 after acquiring an additional 55,407 shares in the last quarter. Essex Investment Management Co. LLC bought a new stake in shares of Travere Therapeutics during the third quarter valued at approximately $3,872,000. Palisades Investment Partners LLC acquired a new position in shares of Travere Therapeutics during the fourth quarter worth approximately $5,264,000. Voya Investment Management LLC raised its position in shares of Travere Therapeutics by 16.2% during the third quarter. Voya Investment Management LLC now owns 194,854 shares of the company's stock worth $4,657,000 after purchasing an additional 27,133 shares during the period. Finally, Lisanti Capital Growth LLC bought a new position in shares of Travere Therapeutics in the 3rd quarter worth $3,095,000.

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in focal segmental glomerulosclerosis (FSGS), expanding Travere’s rare kidney-disease franchise, adding an estimated ~30,000 patients to the U.S. addressable market and supporting multi-year revenue/earnings upside. Article Title
• Positive Sentiment: Market reacted strongly to the approval — shares jumped about ~37% on the news as investors priced in first-mover status, premium pricing potential and material volume-driven revenue growth for Filspari. Article Title
• Positive Sentiment: Multiple brokerages raised ratings/price targets following the approval (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49 overweight, Wedbush to $44, HC Wainwright reaffirmed buy). These upgrades signal increased analyst confidence in TAM expansion and revenue trajectory. Article Title
• Neutral Sentiment: Guggenheim issued a positive forecast note on TVTX that accompanies their price-target lift; this is incremental institutional support but not a guarantee of sustained momentum. Article Title
• Neutral Sentiment: Unusually high options activity and elevated trading volume were reported around the approval-related move, indicating heightened short-term speculation and positioning that can amplify volatility. Article Title
• Neutral Sentiment: Company-hosted commentary/transcripts and mainstream coverage (Seeking Alpha slides/transcript, MSN health reports) are providing more detail on label scope and commercial plans; useful for modeling uptake but not yet concrete sales figures. Article Title
• Negative Sentiment: Some analysts caution that recent earnings-estimate revision trends may limit further near-term upside despite the approval; elevated expectations and heavy short-term speculative flows raise the risk of a pullback or consolidation. Article Title

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on TVTX shares. HC Wainwright restated a "buy" rating and issued a $47.00 price target on shares of Travere Therapeutics in a research report on Tuesday. Citigroup increased their price objective on shares of Travere Therapeutics from $48.00 to $53.00 and gave the stock a "buy" rating in a research note on Tuesday. JPMorgan Chase & Co. decreased their target price on shares of Travere Therapeutics from $44.00 to $41.00 and set an "overweight" rating on the stock in a report on Wednesday, March 25th. Wedbush boosted their target price on shares of Travere Therapeutics from $39.00 to $44.00 and gave the company an "outperform" rating in a research report on Tuesday. Finally, Guggenheim upped their price target on shares of Travere Therapeutics from $49.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.